7.3.1. local therapy advanced/metastatic rcc. 7.3.1.1. cytoreductive nephrectomy tumour resection potentially curative tumour deposits excised. includes patients primary tumour place single- oligometastatic resectable disease. patients metastatic disease, cytoreductive nephrectomy (cn) palliative systemic treatments necessary. combined analysis two rcts comparing cn+ ifn-based immunotherapy vs. ifn-based immunotherapy only, increased long-term survival found patients treated cn . however, ifn-based immunotherapy longer relevant contemporary clinical practice. two rcts narrative sr identified . narrative sr included rcts 10 non-rcts. carmena, phase iii non-inferiority rct investigating immediate cn followed sunitinib vs. sunitinib alone, showed sunitinib alone inferior cn followed sunitinib regard os . trial included 450 patients metastatic ccrcc intermediate- mskcc poor risk 226 randomised immediate cn followed sunitinib 224 sunitinib alone. patients arms median two metastatic sites. patients arms tumour burden median/mean 140 ml measurable disease response evaluation criteria solid tumours (recist) 1.1, 80 ml accounted primary tumour. study reach full accrual 576 patients independent data monitoring commission (idmc) advised trial steering committee close study. itt analysis median follow-up 50.9 months, median os cn 13.9 months vs. 18.4 months sunitinib alone (hr: 0.89, 95% ci: 0.71-1.10). found risk groups. mskcc intermediate-risk patients (n = 256) median os 19.0 months cn 23.4 months sunitinib alone (hr: 0.92, 95% ci: 0.60-1.24) mskcc poor risk (n = 193) 10.2 months 13.3 months, respectively (hr: 0.86, 95% ci: 0.62-1.17). non-inferiority also found two per-protocol analyses accounting patients cn arm either undergo surgery (n = 16) receive sunitinib (n = 40), patients sunitinib-only arm receive study drug (n = 11). median pfs itt population 7.2 months cn 8.3 months sunitinib alone (hr: 0.82, 95% ci: 0.67-1.00). clinical benefit rate, defined disease control beyond twelve weeks 36.6% cn 47.9% sunitinib alone (p = 0.022). note, 38 patients sunitinib-only arm required secondary cn due acute symptoms complete near-complete response. median time randomisation secondary cn 11.1 months. randomised eortc surtime study revealed sequence cn sunitinib affect pfs (hr: 0.88, 95% ci: 0.59-1.37, p = 0.569). trial accrued poorly therefore results mainly exploratory. however, secondary endpoint analysis strong os benefit observed favour deferred cn approach itt population median os 32.4 (range 14.5-65.3) months deferred cn arm vs. 15.0 (9.3-29.5) months immediate cn arm (hr: 0.57, 95% ci: 0.34-0.95, p = 0.032). deferred cn approach appears select patients inherent resistance systemic therapy . confirms previous findings single-arm phase ii studies . moreover, deferred cn surgery appear safe sunitinib supports findings, caution, available rct. patients poor ps imdc poor risk, small primaries, high metastatic volume and/or sarcomatoid tumour, cn recommended . data confirmed carmena upfront pre-surgical vegfr-targeted therapy followed cn seems beneficial . meanwhile first-line therapy recommendations patients primary tumour place changed ici combination therapy (see section 7.4.2.4) sunitinib vegfr-tki monotherapies reserved cannot tolerate ici combination access drugs. high-level evidence regarding cn available ici combinations 30% patients primary metastatic disease, treated tumour place, included pivotal ici combination trials (table 7.2). subgroup hrs, available, suggest better outcomes ici combination compared sunitinib monotherapy. mrcc patients without need immediate drug treatment, sr evaluating effects cn demonstrated os advantage cn . data supported nation-wide registry study showing patients selected primary cn significant os advantage across age groups . table 7.2: key trials immune checkpoint inhibitor combinations primary metastatic disease trialdrug combinationnumber % patients treated primary tumour placenumber patients treated primary tumour place(ici combination vs. sunitinib)subgroup analyses(hr 95% cis)ici combinationsunitinibpfsoscheckmate 214 ipilimumab + nivolumab187/847 (22%)84103na0.63(0.42-0.94)checkmate 9er cabozantinib + nivolumab196/651 (30.1%)101950.63(0.43-0.92)0.79(0.48-1.29)javelin 101 axitinib + avelumab179/886 (20.2%)90890.75(0.48-1.65)nakeynote-426 axitinib + pembrolizumab143/861 (16.6%)73700.68(0.45-1.03)0.57(0.36-0.89)clearlenvatinib + pembrolizumab179/714 (25.1%)97820.38(0.31-0.48)0.52(0.31-0.86) ci = confidence interval; hr = hazard ratio; ici = immune checkpoint inhibitor; na = available;pfs = progression-free survival; os = overall survival. results carmena surtime demonstrated patients require systemic therapy benefit immediate drug treatment. randomised trials investigate deferred vs. cytoreductive nephrectomy ici ici combinations ongoing, exploratory results ici combination trials demonstrate respective immune-oncology (io) + io tki + io combinations superior effect primary tumour metastatic sites compared sunitinib alone (table 7.2). accordance carmena surtime data suggests mrcc patients imdc intermediate- poor-risk groups primary tumour place treated upfront io-based combinations. patients clinical response io-based combinations, subsequent cn may considered. real-world data demonstrated durable response surgical safety strategy, however long-term surveillance lacking [504-506]. 7.3.1.1.1. embolisation primary tumour patients unfit surgery non-resectable disease, embolisation control symptoms including visible haematuria flank pain (see recommendations section 7.1.2.2.4). 7.3.1.1.2. summary evidence recommendations local therapy advanced/metastatic rcc summary evidenceledeferred cn pre-surgical sunitinib intermediate-risk patients clear cell metastatic renal cell carcinoma shows survival benefit secondary endpoint analyses selects patients inherent resistance systemic therapy.2bsunitinib alone non-inferior compared immediate cn followed sunitinib patients mskcc intermediate poor risk require systemic therapy vegfr-tki.1acytoreductive nephrectomy patients simultaneous complete resection single metastasis oligometastases may improve survival delay systemic therapy.3patients mskcc imdc poor risk benefit cn.1apatients primary tumour place treated io-based combination therapy better pfs os exploratory subgroup analyses compared treatment sunitinib.2b recommendationsstrength ratingdo perform cytoreductive nephrectomy (cn) mskcc poor-risk patients.strongdo perform immediate cn intermediate-risk patients asymptomatic synchronous primary tumour require systemic therapy.weakstart systemic therapy without cn intermediate-risk patients asymptomatic synchronous primary tumour require systemic therapy.weakdiscuss delayed cn patients derive clinical benefit systemic therapy.weakperform immediate cn patients good performance status require systemic therapy.weakperform immediate cn patients oligometastases complete local treatment metastases achieved.weak